George Mosialos

6PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 08, 2026
The deubiquitinase activity of CYLD is required for B cell differentiation.

Athanasios Pseftogas, Jessica Bordini, George Gavriilidis

|Sep 15, 2025
The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity.

Stephanie A Fernandes, Jiyoung Pan, Diana S Terziyska

|Oct 28, 2023
Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency.

Nikolaos Bekas, Martina Samiotaki, Maria Papathanasiou

|May 20, 2020
Deubiquitination of NLRP6 inflammasome by Cyld critically regulates intestinal inflammation.

Sandip Mukherjee, Ritesh Kumar, Elviche Tsakem Lenou

|Feb 03, 2018
Functional analysis of the C. elegans cyld-1 gene reveals extensive similarity with its human homolog.

Paul Hadweh, Iro Chaitoglou, Maria Joao Gravato-Nobre

Pageof 1